Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-negative Breast Cancer × Carboplatin × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 243 Triple Negative Breast Neoplasms 125 Neoplasm Metastasis 23 Ovarian Neoplasms 18 Carcinoma, Non-Small-Cell Lung 14 Inflammatory Breast Neoplasms 13 Pancreatic Neoplasms 12 Neoplasms 10 Breast Neoplasms, Male 9 Colorectal Neoplasms 8 Stomach Neoplasms 7 Endometrial Neoplasms 7 Prostatic Neoplasms 6 Sarcoma 5 Pathologic Complete Response 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 Fallopian Tube Neoplasms 5 Carcinoma, Ovarian Epithelial 5 Carcinoma, Ductal, Breast 5 Uterine Cervical Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Melanoma 4 Lung Neoplasms 4 HER2-positive Breast Cancer 4 Urinary Bladder Neoplasms 3 Recurrence 3 Multiple Myeloma 3 Lymphoma, Non-Hodgkin 3 Leukemia, Lymphocytic, Chronic, B-Cell 3 HER2-positive Early Breast Cancer 3

Interventions

eribulin 2 Vinorelbine 2 Paclitaxel 2 Cyclophosphamide 2 trastuzumab deruxtecan 1 taxane 1 sacituzumab govitecan 1 pembrolizumab 1 pamiparib 1 liposomal doxorubicin 1 camrelizumab 1 Precision Medicine 1 Gemcitabine 1 Epirubicin 1 Doxorubicin 1 Docetaxel 1 Cisplatin 1 Carboplatin 1 Capecitabine 1 Anthracyclines 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06102824 2024-11-25

ORIENTA

Guangdong Provincial People's Hospital

Phase 2 Recruiting

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡